🇺🇸 FDA
Pipeline program

Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg

MN39159

Phase 3 small_molecule active

Quick answer

Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg for Progressive multiple sclerosis (PMS) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Progressive multiple sclerosis (PMS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials